title: Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
abstract: OBJECTIVE
  To evaluate the relationships between dose, plasma concentration, pharmacological activity and clinical outcome to evaluate the appropriateness of therapeutic drug monitoring (TDM) in patients receiving amisulpride.
  
  
  METHODS
  Literature search of Embase, Medline and PubMed databases.
  
  
  RESULTS
  Amisulpride plasma concentration is closely correlated with dose (r(2) = 0.96, P < 0.0001), dopamine occupancy, response and with extra-pyramidal symptoms (EPS). Dose is correlated with response, dopamine occupancy and EPS. Optimal clinical response was found at doses of 400-800 mg/day, corresponding to plasma levels of approximately 200-500 ng/ml. EPS appears to be more reliably predicted by a plasma level above 320 ng/ml than by a particular dose.
  
  
  CONCLUSIONS
  The effects and safety of amisulpride in the treatment of schizophrenia and schizoaffective disorder are predicted by daily dose. The plasma concentration threshold for response appears to be approximately 200 ng/ml. EPS are more reliably predicted by plasma level than by dose. TDM for patients prescribed amisulpride is thus of some clinical value.
authors: Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, UK.
authors: A
authors: A
authors: Sparshatt
authors: D
authors: D
authors: Taylor
authors: M X
authors: MX
authors: Patel
authors: S
authors: S
authors: Kapur
mesh_terms: D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D016903:Drug Monitoring; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D011954:Receptors, Dopamine / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D013469:Sulpiride; D000077582:Amisulpride